免疫調整剤の世界市場レポート 2025年

免疫調整剤市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は7.7％で、3,196億7,000万米ドルに成長します。予測期間の成長は、非侵襲的治療に対する患者の嗜好の高まり、規制当局の承認とガイドライン、免疫調節治療に対する医療保険の適用範囲、免疫調節薬の数と進歩、政府のヘルスケア支出などに起因すると考えられます。予測期間における主な動向としては、バイオテクノロジーと免疫療法の進歩、研究開発パイプラインにある免疫調節薬の数と進捗、技術の進歩、個別化医療の傾向、免疫腫瘍学の進歩などが挙げられます。

慢性疾患の増加は、今後数年間の免疫調整剤市場の成長を大きく牽引すると予想されます。慢性疾患は、徐々に発症し、長期間（多くの場合、生涯）にわたって持続する長期的な病状です。慢性疾患の増加は、人口の高齢化、ライフスタイルの選択、遺伝的素因、ヘルスケアシステムの利用可能性とインフラなどの要因によって促進されます。免疫調節剤は、免疫反応を調節し、炎症を抑え、臓器拒絶反応を予防し、免疫監視を強化し、症状コントロールを改善することにより、慢性疾患の管理に重要な役割を果たしています。例えば、2023年9月、世界保健機関（WHO）は、世界の死亡者数の74％を占める4,100万人が非感染性疾患（NCDs）または慢性疾患に起因すると報告しました。その内訳は、心血管疾患による死亡が1,790万人、がんによる死亡が930万人、慢性呼吸器疾患による死亡が410万人、糖尿病による死亡が200万人です。その結果、慢性疾患の負担の増大が免疫調節剤の需要を牽引しています。

免疫調整剤市場の各社は、免疫機能を低下させることなく免疫反応を調節する治療に対する需要の高まりに対応するため、非免疫抑制剤の開発にますます力を注いでいます。非免疫抑制性治療は、免疫系を抑制したり弱めたりするものではないです。例えば、米国を拠点とするバイオテクノロジー企業Nuvig Therapeutics, Inc.は2024年2月、次世代免疫調節剤NVG-2089の初期段階の臨床試験を開始しました。NVG-2089は、炎症性ミオパチーや重症の皮膚自己免疫疾患の患者を治療するためにデザインされました。FDAはNVG-2089の水疱性類天疱瘡の開発について、ファスト・トラック指定を行いました。この革新的な組換え型非免疫抑制薬は、II型Fcレセプターを標的とし、自己免疫調節異常を緩和する内因性調節機構を活性化します。本試験の第一目的はNVG-2089の安全性と忍容性を評価することであり、第二目的は薬物動態と薬力学に焦点を当てています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界免疫調整剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の免疫調整剤市場：成長率分析
• 世界の免疫調整剤市場の実績：規模と成長, 2019-2024
• 世界の免疫調整剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界免疫調整剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の免疫調整剤市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• 免疫刺激剤
• その他の製品タイプ
• 世界の免疫調整剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル
• 世界の免疫調整剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 呼吸器
• ヒト免疫不全ウイルス
• その他の用途
• 世界の免疫調整剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界の免疫調整剤市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• カルシニューリン阻害剤（タクロリムス、シクロスポリン）
• MTOR阻害剤（シロリムス、エベロリムス）
• 代謝拮抗薬（アザチオプリン、メトトレキサート）
• 生物学的免疫抑制剤（リツキシマブのようなモノクローナル抗体）
• ヤヌスキナーゼ（JAK）阻害剤
• T細胞阻害剤
• その他の免疫抑制剤
• 世界の免疫調整剤市場免疫刺激剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サイトカインおよび成長因子ベースの免疫刺激剤（インターフェロン、インターロイキン）
• 免疫刺激のためのモノクローナル抗体
• ワクチン（がんワクチン、予防ワクチン）
• アジュバントおよび免疫調節剤
• 自己免疫疾患に対する免疫刺激剤
• Toll様受容体（TLR）作動薬
• 核酸系免疫刺激剤（DNAまたはRNAワクチン）
• 世界の免疫調整剤市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤（融合タンパク質、免疫チェックポイント阻害剤）
• 低分子免疫調節剤
• 免疫療法薬
• 幹細胞ベースの免疫調節剤
• 免疫腫瘍薬
• プロバイオティクスおよびその他の天然免疫調節剤

第7章 地域別・国別分析

• 世界の免疫調整剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の免疫調整剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫調整剤市場：競合情勢
• 免疫調整剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A
• Bristol Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Applied Molecular Genetics Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• UCB S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 免疫調整剤市場2029：新たな機会を提供する国
• 免疫調整剤市場2029：新たな機会を提供するセグメント
• 免疫調整剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

An immunomodulator is a substance or medication utilized to modify or regulate the activity of the immune system, often employed in the treatment of various medical conditions. The specific application of immunomodulators varies depending on the underlying condition being addressed and the desired effect on immune response.

The primary product categories within the immunomodulator market comprise immunosuppressants, immunostimulants, and other product types. Immunosuppressants are medications designed to weaken the body's immune system, thereby reducing its capacity to combat diseases and foreign substances. These products are distributed through channels including hospital pharmacies, online pharmacies, retail pharmacies, and other distribution channels. They find application across various medical fields such as oncology, respiratory diseases, human immunodeficiency virus (HIV), among others, and are utilized by a range of end-users including hospitals, clinics, and others.

The immunomodulator market research report is one of a series of new reports from The Business Research Company that provides immunomodulator market statistics, including immunomodulator industry global market size, regional shares, competitors with an immunomodulator market share, detailed immunomodulator market segments, market trends, and opportunities, and any further data you may need to thrive in the immunomodulator industry. This immunomodulator research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunomodulator market size has grown strongly in recent years. It will grow from $219.94 billion in 2024 to $237.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to healthcare infrastructure development, increased awareness among patients, the aging population, increasing incidence of autoimmune diseases, and the introduction of biologic drugs.

The immunomodulator market size is expected to see strong growth in the next few years. It will grow to $319.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing patient preference for non-invasive, regulatory approvals and guidelines, the extent of health insurance coverage for immunomodulatory treatments, the number and progress of immunomodulatory drugs, and government healthcare expenditure. Major trends in the forecast period include advancements in biotechnology and immunotherapy, the number and progress of immunomodulatory drugs in the research and development pipeline, advances in technology, the trend towards personalized medicine, and advancements in immuno-oncology.

The increasing prevalence of chronic diseases is anticipated to significantly drive the growth of the immunomodulator market in the coming years. Chronic diseases are long-term medical conditions that develop gradually and persist for extended periods, often for a lifetime. The rise in chronic diseases is fueled by factors such as an aging population, lifestyle choices, genetic predispositions, and the availability and infrastructure of healthcare systems. Immunomodulators play a crucial role in managing chronic diseases by modulating immune responses, reducing inflammation, preventing organ rejection, enhancing immune surveillance, and improving symptom control. For instance, in September 2023, the World Health Organization (WHO) reported that 41 million deaths, accounting for 74% of all global deaths, were attributed to non-communicable diseases (NCDs) or chronic diseases. These included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the growing burden of chronic diseases is driving the demand for immunomodulators.

Companies in the immunomodulator market are increasingly focusing on developing non-immunosuppressive products to meet the rising demand for treatments that modulate immune responses without compromising overall immune function. Non-immunosuppressive treatments do not suppress or weaken the immune system. For example, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, commenced early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is designed to treat patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA has granted fast-track designation for NVG-2089's development in treating bullous pemphigoid. This innovative, recombinant, non-immunosuppressive immunomodulator targets type II Fc receptors to activate an endogenous regulatory mechanism that mitigates autoimmune dysregulation. The primary objective of the study is to evaluate the safety and tolerability of NVG-2089, with secondary objectives focusing on its pharmacokinetics and pharmacodynamics.

In February 2022, Equillium, Inc., a US-based biotechnology company, acquired Bioniz Therapeutics Inc. for an undisclosed amount. This acquisition significantly expanded Equillium's immunology pipeline by incorporating two first-in-class clinical-stage assets and a proprietary product discovery platform. Bioniz Therapeutics Inc., a US-based company, develops cytokine-targeted medicines for treating immuno-inflammatory disorders and cancer, which are part of the immunomodulator category. This acquisition underscores the strategic importance of expanding product portfolios to include innovative immunomodulatory treatments.

Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Ipsen SA, Kyowa Kirin Co. Ltd., Amicus Therapeutics Inc.

North America was the largest region in the immunomodulator market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immunomodulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immunomodulator market consists of sales of herbal immunomodulators, vaccines, immunomodulatory drugs, monoclonal antibodies, and interferons. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunomodulator Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunomodulator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunomodulator ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunomodulator market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Immunosuppressants; Immunostimulants; Other Product Types
• 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 3) By Application: Oncology; Respiratory; Human Immunodeficiency Virus; Other Applications
• 4) By End-User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Immunosuppressants: Corticosteroids; Calcineurin Inhibitors (Tacrolimus, Cyclosporine); Mtor Inhibitors ( Sirolimus, Everolimus); Antimetabolites ( Azathioprine, Methotrexate); Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab); Janus Kinase (Jak) Inhibitors; T-Cell Inhibitors; Other Immunosuppressive Agents
• 2) By Immunostimulants: Cytokine And Growth Factor-Based Immunostimulants ( Interferons, Interleukins); Monoclonal Antibodies For Immune Stimulation; Vaccines ( Cancer Vaccines, Preventive Vaccines); Adjuvants And Immune Modulatory Agents; Immunostimulatory Agents For Autoimmune Diseases; Toll-Like Receptor (Tlr) Agonists; Nucleic Acid-Based Immunostimulants ( Dna Or Rna Vaccines)
• 3) By Other Product Types: Biologics ( Fusion Proteins, Immune Checkpoint Inhibitors); Small Molecule Immunomodulators; Immunotherapy Drugs; Stem Cell-Based Immunomodulators; Immuno-Oncology Drugs; Probiotics And Other Natural Immunomodulatory Agents
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immunomodulator Market Characteristics

3. Immunomodulator Market Trends And Strategies

4. Immunomodulator Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Immunomodulator Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immunomodulator PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immunomodulator Market Growth Rate Analysis
• 5.4. Global Immunomodulator Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immunomodulator Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immunomodulator Total Addressable Market (TAM)

6. Immunomodulator Market Segmentation

• 6.1. Global Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Immunostimulants
• Other Product Types
• 6.2. Global Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.3. Global Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Respiratory
• Human Immunodeficiency Virus
• Other Applications
• 6.4. Global Immunomodulator Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.5. Global Immunomodulator Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Calcineurin Inhibitors (Tacrolimus, Cyclosporine)
• MTOR Inhibitors (Sirolimus, Everolimus)
• Antimetabolites (Azathioprine, Methotrexate)
• Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab)
• Janus Kinase (JAK) Inhibitors
• T-Cell Inhibitors
• Other Immunosuppressive Agents
• 6.6. Global Immunomodulator Market, Sub-Segmentation Of Immunostimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytokine And Growth Factor-Based Immunostimulants (Interferons, Interleukins)
• Monoclonal Antibodies For Immune Stimulation
• Vaccines (Cancer Vaccines, Preventive Vaccines)
• Adjuvants And Immune Modulatory Agents
• Immunostimulatory Agents For Autoimmune Diseases
• Toll-Like Receptor (TLR) Agonists
• Nucleic Acid-Based Immunostimulants (DNA Or RNA Vaccines)
• 6.7. Global Immunomodulator Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics (Fusion Proteins, Immune Checkpoint Inhibitors)
• Small Molecule Immunomodulators
• Immunotherapy Drugs
• Stem Cell-Based Immunomodulators
• Immuno-Oncology Drugs
• Probiotics And Other Natural Immunomodulatory Agents

7. Immunomodulator Market Regional And Country Analysis

• 7.1. Global Immunomodulator Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immunomodulator Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immunomodulator Market

• 8.1. Asia-Pacific Immunomodulator Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immunomodulator Market

• 9.1. China Immunomodulator Market Overview
• 9.2. China Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immunomodulator Market

• 10.1. India Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immunomodulator Market

• 11.1. Japan Immunomodulator Market Overview
• 11.2. Japan Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immunomodulator Market

• 12.1. Australia Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immunomodulator Market

• 13.1. Indonesia Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immunomodulator Market

• 14.1. South Korea Immunomodulator Market Overview
• 14.2. South Korea Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immunomodulator Market

• 15.1. Western Europe Immunomodulator Market Overview
• 15.2. Western Europe Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immunomodulator Market

• 16.1. UK Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immunomodulator Market

• 17.1. Germany Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immunomodulator Market

• 18.1. France Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immunomodulator Market

• 19.1. Italy Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immunomodulator Market

• 20.1. Spain Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immunomodulator Market

• 21.1. Eastern Europe Immunomodulator Market Overview
• 21.2. Eastern Europe Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immunomodulator Market

• 22.1. Russia Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immunomodulator Market

• 23.1. North America Immunomodulator Market Overview
• 23.2. North America Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immunomodulator Market

• 24.1. USA Immunomodulator Market Overview
• 24.2. USA Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immunomodulator Market

• 25.1. Canada Immunomodulator Market Overview
• 25.2. Canada Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immunomodulator Market

• 26.1. South America Immunomodulator Market Overview
• 26.2. South America Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immunomodulator Market

• 27.1. Brazil Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immunomodulator Market

• 28.1. Middle East Immunomodulator Market Overview
• 28.2. Middle East Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immunomodulator Market

• 29.1. Africa Immunomodulator Market Overview
• 29.2. Africa Immunomodulator Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immunomodulator Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immunomodulator Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immunomodulator Market Competitive Landscape And Company Profiles

• 30.1. Immunomodulator Market Competitive Landscape
• 30.2. Immunomodulator Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Immunomodulator Market Other Major And Innovative Companies

• 31.1. Sanofi S.A
• 31.2. Bristol Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Applied Molecular Genetics Inc.
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Biogen Inc.
• 31.14. Vertex Pharmaceuticals Incorporated
• 31.15. UCB S.A.

32. Global Immunomodulator Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immunomodulator Market

34. Recent Developments In The Immunomodulator Market

35. Immunomodulator Market High Potential Countries, Segments and Strategies

• 35.1 Immunomodulator Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immunomodulator Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immunomodulator Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer